The University of Chicago Header Logo

Connection

Tao Xie to Male

Back to Details
This is a "connection" page, showing publications Tao Xie has written about Male.
Tao Xie
Connection Strength
0.716
Male
  1. Healthcare access and utilization of deep brain stimulation and supplementary care in black and white patients with Parkinson's disease. Parkinsonism Relat Disord. 2025 Nov; 140:108057.
    View in: PubMed
    Score: 0.046
  2. Multiple System Atrophy. Continuum (Minneap Minn). 2025 Aug; 31(4):1000-1022.
    View in: PubMed
    Score: 0.046
  3. Bedside Assessment of Downgaze Limit by Amplitude. Mov Disord Clin Pract. 2025 Dec; 12(12):2224-2231.
    View in: PubMed
    Score: 0.046
  4. Effect of dopaminergic medications on Montreal Cognitive Assessment in Parkinson's disease patients. Parkinsonism Relat Disord. 2025 Sep; 138:107951.
    View in: PubMed
    Score: 0.046
  5. Disparities in diagnosis, treatment and survival between Black and White Parkinson patients. Parkinsonism Relat Disord. 2021 06; 87:7-12.
    View in: PubMed
    Score: 0.034
  6. Interference of subcutaneous implantable cardioverter defibrillator by deep brain stimulation. Parkinsonism Relat Disord. 2020 12; 81:75-77.
    View in: PubMed
    Score: 0.033
  7. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018 09; 89(9):989-994.
    View in: PubMed
    Score: 0.028
  8. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
    View in: PubMed
    Score: 0.025
  9. Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy. Mov Disord. 2025 Nov; 40(11):2517-2530.
    View in: PubMed
    Score: 0.023
  10. Author Response. Neurology. 2015 Aug 11; 85(6):557.
    View in: PubMed
    Score: 0.023
  11. Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS. Neurology. 2015 Aug 04; 85(5):479-80.
    View in: PubMed
    Score: 0.023
  12. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015 Jan 27; 84(4):415-20.
    View in: PubMed
    Score: 0.022
  13. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials. Mov Disord. 2024 Aug; 39(8):1329-1342.
    View in: PubMed
    Score: 0.021
  14. GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians. Mov Disord. 2024 Apr; 39(4):728-733.
    View in: PubMed
    Score: 0.021
  15. DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology. 2014 Feb 18; 82(7):636-7.
    View in: PubMed
    Score: 0.021
  16. Diagnostic biomarkers of Parkinson's disease: what gain at what cost? J Neurol Neurosurg Psychiatry. 2012 Aug; 83(8):769.
    View in: PubMed
    Score: 0.018
  17. Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Oct; 83(10):1015-7.
    View in: PubMed
    Score: 0.018
  18. Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord. 2012 May; 27(6):799-800.
    View in: PubMed
    Score: 0.018
  19. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
    View in: PubMed
    Score: 0.014
  20. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
    View in: PubMed
    Score: 0.014
  21. Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017 Feb 07; 88(6):543-550.
    View in: PubMed
    Score: 0.013
  22. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
    View in: PubMed
    Score: 0.012
  23. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology. 2006 Dec; 31(12):2639-51.
    View in: PubMed
    Score: 0.012
  24. Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome. Alzheimers Dement. 2025 Jul; 21(7):e70485.
    View in: PubMed
    Score: 0.011
  25. Automated Imaging Differentiation for Parkinsonism. JAMA Neurol. 2025 May 01; 82(5):495-505.
    View in: PubMed
    Score: 0.011
  26. The Black and African American Connections to Parkinson's Disease (BLAAC PD) study protocol. BMC Neurol. 2024 Oct 21; 24(1):403.
    View in: PubMed
    Score: 0.011
  27. Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B). Ann Neurol. 2024 Dec; 96(6):1092-1103.
    View in: PubMed
    Score: 0.011
  28. Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons. J Neurosci. 2004 Aug 11; 24(32):7043-50.
    View in: PubMed
    Score: 0.011
  29. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.011
  30. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2002 Jan 01; 22(1):274-83.
    View in: PubMed
    Score: 0.009
  31. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2000 Oct 15; 20(20):7838-45.
    View in: PubMed
    Score: 0.008
  32. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.008
  33. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp. 2019 12 01; 40(17):5094-5107.
    View in: PubMed
    Score: 0.008
  34. Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 08; 65:178-183.
    View in: PubMed
    Score: 0.008
  35. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
    View in: PubMed
    Score: 0.007
  36. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 02; 33(2):282-288.
    View in: PubMed
    Score: 0.007
  37. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. 1997 May; 12(3):426-7.
    View in: PubMed
    Score: 0.006
  38. Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. 2016 12; 31(12):1874-1882.
    View in: PubMed
    Score: 0.006
  39. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32.
    View in: PubMed
    Score: 0.006
  40. A murine dopamine neuron-specific cDNA library and microarray: increased COX1 expression during methamphetamine neurotoxicity. Neurobiol Dis. 2001 Oct; 8(5):822-33.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.